Natalicchio, A.
Marrano, N.
Montagnani, M.
Gallo, M.
Faggiano, A.
Zatelli, MC
Argentiero, A.
Del Re, M.
D’Oronzo, S.
Fogli, S.
Franchina, T.
Giuffrida, D.
Gori, S.
Ragni, A.
Marino, G.
Mazzilli, R.
Monami, M.
Morviducci, L.
Renzelli, V.
Russo, A.
Sciacca, L.
Tuveri, E.
Cortellini, A.
Di Maio, M.
Candido, R.
Perrone, F.
Aimaretti, G.
Avogaro, A.
Silvestris, N.
Giorgino, F. http://orcid.org/0000-0001-7372-2678
Funding for this research was provided by:
Università degli Studi di Bari Aldo Moro
Article History
Received: 12 April 2024
Accepted: 16 June 2024
First Online: 27 June 2024
Declarations
:
: M.G. has received honoraria for speaker fees and/or travel grants for scientific meetings from AAA, AstraZeneca, Boehringer-Ingelheim, Bruno Farm, Eli-Lilly, IBSA, Lifescan, Mundipharma, Novo Nordisk and Sanofi, and served on scientific advisory panels for Boehringer-Ingelheim, Merck Sharp & Dohme and Novo Nordisk. S.F. serves on the scientific advisory board of, has a consulting relationship with and reports receiving support for travel expenses from Novartis, Teva, Roche, BMS, Lilly and Ipsen. S.G. serves on the scientific advisory board of, has a consulting relationship with and reports receiving support for travel expenses from Novartis, Teva, Roche, BMS, Lilly and Ipsen. A.R. has received a travel grant from Movi and IBSA. M.M. reports direct competing interests with Sanofi. V.R. has received a travel grant from Androlabs. A.C. received grants for consultancies/advisory boards from BMS, MSD, OncoC4, IQVIA, Roche, GSK, AstraZeneca, Access Infinity, Ardelis Health and REGENERON; he also received speaker fees from AstraZeneca, EISAI, MSD, SANOFI/REGENERON and Pierre-Fabre. M.D.M reports honoraria from AstraZeneca, Janssen, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Roche, GlaxoSmithKline, Amgen, Merck, Takeda, Ipsen for consultancy or participation to advisory boards; direct research funding from Tesaro/GlaxoSmithKline; institutional funding for work in clinical trials/contracted research from Beigene, Exelixis, MSD, Pfizer and Roche. R.C. reports honoraria for advisory board from Novo-Nordisk, Sanofi; consulting feed from Abbott, Sanofi, Eli Lilly, Bayer, Novo Nordisk, MSD, Menarini Diagnostics; payment for lectures, presentation, speaker from Eli Lilly, Boehringer Ingelheim, Novi Nordisk, Roche Diabetes Care, Sanofi. F.P. declares institutional grants or contracts from Roche, Bayer, AstraZeneca, Pfizer, Incyte, Tesaro/GSK, Merck; consulting fees from Bayer, Pierre Fabre, Astra Zeneca, Incyte, Ipsen, Clovis, Astellas, Sanofi, Roche, Pfizer; leadership in scientific society: President of AIOM 2023–2025. G.A. received grants for advisory board from Sanofi, NN, Eli-lilly. N.S. received fees for consulting from from Bristol, Roche, Eisai, Servier. F.G. has served as an advisor for AstraZeneca, Eli Lilly and Novo Nordisk; has served as a research investigator for Eli Lilly and Roche Diabetes Care; has served as a speaker for AstraZeneca and Eli Lilly; has served as a consultant for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche Diabetes Care and Sanofi; and has received grants from Eli Lilly, Lifescan and Roche Diabetes Care. All other authors declare no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: No Informed Consent.